Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Beijing Biotech
Beijing Biotech
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Nanfang Hospital, Southern Medical University
University of Miami
Tulane University
Emory University
Vanderbilt-Ingram Cancer Center
Herlev Hospital
St. Anna Kinderkrebsforschung
Fate Therapeutics
Fate Therapeutics
Zealand University Hospital
Roswell Park Cancer Institute
The First Affiliated Hospital of Soochow University
Ottawa Hospital Research Institute
Zealand University Hospital
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Senlang Biotechnology Inc., Ltd.
Peking University People's Hospital
Roswell Park Cancer Institute
Seoul National University Hospital
Yale University
M.D. Anderson Cancer Center
Washington University School of Medicine
Wake Forest University Health Sciences
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
The Royal Bournemouth Hospital
St. Jude Children's Research Hospital
Rochester General Hospital
St. Antonius Hospital
Stony Brook University
Roswell Park Cancer Institute
Chiltern Pesquisa Clinica Ltda